Taishi Harada
Fukuchiyama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 148 publications
Predictive value of TTF-1 expression for stratifying outcomes between dual ICI and chemoimmunotherapy in patients with PD-L1-negative NSCLC.
Journal: International journal of clinical oncology
Published: April 21, 2026
Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance.
Journal: Anticancer research
Published: February 28, 2026
Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
Clinical Outcomes and Acute Exacerbation Incidence in Combined Pulmonary Fibrosis and Emphysema.
Journal: Respirology (Carlton, Vic.)
Published: February 04, 2026
Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria.
Journal: Journal of cachexia, sarcopenia and muscle
Published: November 24, 2025
Initial biomarker testing strategies and clinical outcomes in advanced non-small cell lung cancer.
Journal: iScience
Published: October 02, 2025
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy.
Journal: Translational lung cancer research
Published: July 28, 2025
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 06, 2025
Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 05, 2025
Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.
Journal: JTO clinical and research reports
Published: June 16, 2025
Association of TP53 gain-of-function mutations with early osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma.
Journal: ESMO open
Published: June 06, 2025
Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer.
Journal: ESMO open
Published: May 27, 2025
Last Updated: 09/26/2026